Marker proteins of these signaling pathways, for instance, TGFBRI (transforming-beta type I receptor) [10] and CTGF [11], etc., were reported to be the targets of anti-IPF drugs. The gene discussed is CCN2; the disease is idiopathic pulmonary fibrosis.